BioCentury
ARTICLE | Clinical News

Visterra reports preclinical data for dengue fever candidate

February 23, 2018 3:22 PM UTC

Visterra Inc. (Cambridge, Mass.) reported preclinical data from mouse models of primary and secondary dengue fever infection showing that VIS513 significantly reduced viral titers vs. controls and protected mice from lethal infections. Data were published in PLOS Neglected Tropical Diseases.

In 2015, Visterra granted Serum Institute of India Ltd. (Pune, India) an exclusive license to develop and commercialize VIS513 in India, Pakistan, Bangladesh, Nepal, Bhutan, Maldives and Sri Lanka. Serum Institute of India plans to start clinical testing of VIS513 this year (see BioCentury, Oct. 12, 2015)...